肝癌患者经导管动脉化学药物栓塞术前后血清肝细胞生长因子水平变化及其临床意义

目的: 研究肝癌患者经导管动脉化学药物栓塞术(TACE) 前后血清肝细胞生长因子(HGF)水平的动态变化及其影响因素, 探讨其临床意义。方法: 以30 例慢性乙型肝炎基础上的肝癌患者为研究对象, 用酶联免疫法(ELISA) 测定TACE 术前1 天, 术后第3 、7 、28 天血清HGF 浓度, 分析TACE前后血清HGF 水平动态变化及其影响因素。以10 例健康献血者为正常对照组, 10 例慢性乙型肝炎患者及10 例慢性乙型肝炎肝硬化患者为慢性肝炎组和肝硬化组。结果: 肝癌患者TACE 术前血清HGF 浓度为(0.63 ±0.28) ng /mL], 显著高于正常对照组(0.17 ±0.04) ng /mL] 、慢性肝炎组(0.35 ±0.08) ng /mL] 以及肝硬化组(0.39 ±0.09) ng /mL] (P <0.05) 。TACE 术后血清HGF浓度上升高峰出现在术后第3 天(1.37 ±0.21) ng /mL], 术后第7 天逐渐下降(0.79 ±0.14) ng /mL], 术后第28 天基本恢复术前水平(0.66 ±0.19) ng /mL] 。TACE 术后有肿瘤转移的肝癌患者, 其术前血清HGF 水平显著高于无肿瘤转移的患者(0.94 ±0.18) ng /mL vs (0.51 ±0.23) ng /mL, P <0.05] 。栓塞范围超过1 2 肝脏体积的肝癌患者术后第3 天血清HGF 水平上升更明显(1.74 ± 0.16) ng /mL vs (1.16 ±0.17) ng /mL, P <0.05] 。结论: 血清HGF 水平可作为肝癌诊断和TACE 治疗后随访的肿瘤标记物之一, 肝癌患者TACE 术后血清HGF 水平的持续升高可能与术后肿瘤转移有关。

Changes of hepatocyte growth factor concentration in serum after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and its clinical significance

AIM: To analyze the changes of hepatocyte growth factor(HGF) concentration in serum after transcatheter arterial chemoembolization (TACE) for patients with hepatocellular carcinoma and its clinical significance. METHODS: Thirty patients with hepatic cellular cancer (HCC) undergoing TACE were studied. Serum HGF levels were determined using ELISA kit before and after TACE respectively. The correlations of clinical pathologic parameters with the serum HGF concentration were analyzed respectively. Serum HGF concentrations of 10 healthy blood donors and 10 patients with chronic viral hepatitis B (CH) and 10 patients with liver cirrhosis(LC) were studied as control respectively. RESULTS: The mean HGF level in the HCC group was significantly higher than those in the normal controls, the CH group and the LC group(0.63 ± 0.28) ng /mL vs (0.17 ±0.04) ng /mL, (0.35 ± 0.08) ng /mL and (0.39 ±0.09) ng /mL, P <0.05]. There was a peak of serum HGF concentrations on the third day after TACE(1.37 ±0.21) ng /mL], and the HGF level declined on the seventh day(0.79 ±0.14) ng /mL], and then returned to normal level on the twenty-eighth day(0.66 ±0.19) ng /mL]. The patients with metastases after TACE had a higher level of serum HGF than others (0.94 ±0.18) ng /mL vs (0.51 ±0.23) ng /mL, P <0.05]. The patients who were treated with larger volumes had a higher level of serum HGF than those who were treated with smaller volumes on the third day after TACE (1.74 ±0.16) ng /mL vs (1.16 ±0.17) ng /mL, P <0.05]. CONCLUSION: Serum HGF level is a useful tumor marker and an indicator of prognosis for patients with HCC, the sustained high level of HGF may be a factor related to early tumor metastases.